As part of cost-cutting efforts, Alector is letting go of about 25 people as it focuses on advancing its preclinical and ...

Dr. Salvadore is an established industry executive physician and leader with more than 15 years of experience leading neurology-focused clinical development functions. He joined Alector in 2023 as ...

Alector said it has decided to cut about 25 employees, or 13% of its headcount, to reduce costs. The biotech company, which had been developing an Alzheimer drug candidate that missed trial ...

Morgan Stanley analyst Sean Laaman assumed coverage of Alector (ALEC) with an Underweight rating and a price target of $1.50, down from $3. The ...

March 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of ...

Alector (NASDAQ:ALEC) is scheduled to announce Q4 earnings results on Wednesday, February 26th, after market close.The consensus EPS Estimate is -$0.54 (-10.2% Y/Y) and the consensus Revenue ...

Alector said Gary Romano is stepping down as medical chief after about three years in the role, and will be replaced by Giacomo Salvadore. The late-stage clinical biotechnology company with a focus on ...

The last time I wrote an article on Alector, Inc. (NASDAQ:ALEC), I analyzed its enormous potential in using its TREM2 receptor drug AL002 being studied in the phase 2 INVOKE-2 trial, which was ...

A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http ...

March 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...